Monoclonal antibody M195-Y-90

Drug Profile

Monoclonal antibody M195-Y-90

Alternative Names: Anti-CD33 Yttrium-90-labelled monoclonal antibody; Yttrium-90-labelled human M195 monoclonal antibody

Latest Information Update: 05 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Cancer

Most Recent Events

  • 25 Jul 2000 Phase-I clinical trials for Acute myeloid leukaemia in USA (IV-infusion)
  • 25 Jul 2000 A phase I study in AML has been added to the therapeutic trials and adverse events sections
  • 12 May 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top